NAUT · NASDAQ
Nautilus Biotechnology (NAUT) Stock Price & Fundamentals
Nautilus Biotechnology (NAUT) closed at $635.64 on Oct 9, 2026, down 1.29% from the previous close of $643.97.
Share price, past year
1Y +17.03%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $635.64 |
| Sep 30, 2026 | $635.62 |
| Aug 31, 2026 | $638.92 |
| Jul 31, 2026 | $633.97 |
| Jun 30, 2026 | $603.36 |
| May 29, 2026 | $606.14 |
| Apr 30, 2026 | $613.83 |
| Mar 31, 2026 | $620.09 |
| Feb 27, 2026 | $615.19 |
| Jan 30, 2026 | $603.69 |
| Dec 31, 2025 | $562.56 |
| Nov 28, 2025 | $543.00 |
| Oct 31, 2025 | $562.13 |
Key statistics
- Market cap
- $80.89B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.45
- Revenue (TTM)
- —
- Net income (TTM)
- −$56.52M
- Shares outstanding
- 127.3M
- Dividend yield
- —
- 52-week range
- $537.15 – $672.15
Nautilus Biotechnology's market cap is $80.89B, based on a share price of $635.64 and 127.3M shares outstanding as of Jul 24, 2026.
Financials
Nautilus Biotechnology reported a net loss of $59.00M in fiscal 2025.
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $190.00K | −$14.47M | −$0.11 |
| Q1 FY2026ended Mar 31, 2026 | $0.00 | −$14.70M | −$0.12 |
| Q2 FY2025ended Jun 30, 2025 | $0.00 | −$15.03M | −$0.12 |
| Q1 FY2025ended Mar 31, 2025 | $0.00 | −$16.61M | −$0.13 |
Earnings
Nautilus Biotechnology lost $0.11 per share in fiscal Q2 2026, reported Jul 28, 2026, compared with a loss of $0.12 a year earlier.
Diluted earnings per share by quarter
| Quarter | Reported | EPS (diluted) | A year earlier | Change |
|---|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | Jul 28, 2026Earnings release | −$0.11 | −$0.12 | — |
| Q1 FY2026ended Mar 31, 2026 | Apr 28, 2026Earnings release | −$0.12 | −$0.13 | — |
| Q4 FY2025ended Dec 31, 2025Full year minus Q1–Q3 | Feb 26, 2026Earnings release | −$0.11 | −$0.14 | — |
| Q3 FY2025ended Sep 30, 2025 | Oct 28, 2025Earnings release | −$0.11 | −$0.13 | — |
| Q2 FY2025ended Jun 30, 2025 | Jul 31, 2025Earnings release | −$0.12 | −$0.14 | — |
| Q1 FY2025ended Mar 31, 2025 | Apr 29, 2025Earnings release | −$0.13 | −$0.15 | — |
| Q4 FY2024ended Dec 31, 2024Full year minus Q1–Q3 | Feb 27, 2025Earnings release | −$0.14 | −$0.13 | — |
| Q3 FY2024ended Sep 30, 2024 | Oct 29, 2024Earnings release | −$0.13 | −$0.13 | — |
About Nautilus Biotechnology
- Name
- Nautilus Biotechnology, Inc.
- Ticker
- NAUT
- Exchange
- NASDAQ
- Employees
- 130as of Dec 31, 2025 (10-K)
- Industry (SEC SIC)
- Laboratory Analytical Instruments
- Headquarters
- 2701 Eastlake Ave East, Seattle, WA 98102
- Fiscal year ends
- December
- SEC CIK
- 0001808805
Recent SEC filings
- Sep 11, 2026
- Jul 28, 2026
- Jul 28, 2026
- Jun 18, 2026
- Apr 28, 2026
- Apr 28, 2026
- Feb 26, 2026
- Feb 26, 2026
ETFs that hold Nautilus Biotechnology
Of the ETFs and funds on Laurel, Vanguard Morningstar Total Stock Market ETF (VTI) holds the most Nautilus Biotechnology shares by value: 0.00% of the fund, as of its latest report to the SEC.
Frequently asked questions
What is Nautilus Biotechnology's stock price?
Nautilus Biotechnology (NAUT) closed at $635.64 on Oct 9, 2026, down 1.29% from the previous close of $643.97.
What is Nautilus Biotechnology's market cap?
Nautilus Biotechnology's market cap is $80.89B, based on a share price of $635.64 and 127.3M shares outstanding as of Jul 24, 2026.
Does Nautilus Biotechnology pay a dividend?
Nautilus Biotechnology's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Nautilus Biotechnology, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 10, 2026. Data sources and disclosures